BRPI0814797A2 - Inibidores dna-pk - Google Patents

Inibidores dna-pk

Info

Publication number
BRPI0814797A2
BRPI0814797A2 BRPI0814797-3A2A BRPI0814797A BRPI0814797A2 BR PI0814797 A2 BRPI0814797 A2 BR PI0814797A2 BR PI0814797 A BRPI0814797 A BR PI0814797A BR PI0814797 A2 BRPI0814797 A2 BR PI0814797A2
Authority
BR
Brazil
Prior art keywords
inhibitors
dna
Prior art date
Application number
BRPI0814797-3A2A
Other languages
English (en)
Inventor
Mark Frigerio
Marc Geoffrey Hummersone
Keith Allan Menear
Christine Sarah Bailey
Heather Mary Ellen Duggan
Sylvie Gomez
Niall Morrison Barr Martin
Original Assignee
Kudos Pharm Ltd
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791057&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814797(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kudos Pharm Ltd, Cancer Rec Tech Ltd filed Critical Kudos Pharm Ltd
Publication of BRPI0814797A2 publication Critical patent/BRPI0814797A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
BRPI0814797-3A2A 2007-07-19 2008-07-18 Inibidores dna-pk BRPI0814797A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95063107P 2007-07-19 2007-07-19
US3656008P 2008-03-14 2008-03-14
PCT/GB2008/002459 WO2009010761A1 (en) 2007-07-19 2008-07-18 Dna pk inhibitors

Publications (1)

Publication Number Publication Date
BRPI0814797A2 true BRPI0814797A2 (pt) 2015-02-03

Family

ID=39791057

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814797-3A2A BRPI0814797A2 (pt) 2007-07-19 2008-07-18 Inibidores dna-pk

Country Status (14)

Country Link
US (1) US20090042865A1 (pt)
EP (1) EP2176254A1 (pt)
JP (1) JP2010533694A (pt)
KR (1) KR20100063701A (pt)
CN (1) CN101754964A (pt)
AR (1) AR067613A1 (pt)
AU (1) AU2008277418A1 (pt)
BR (1) BRPI0814797A2 (pt)
CA (1) CA2693926A1 (pt)
CL (1) CL2008002130A1 (pt)
RU (1) RU2009149210A (pt)
TW (1) TW200918528A (pt)
UY (1) UY31232A1 (pt)
WO (1) WO2009010761A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
WO2005016919A1 (en) * 2003-08-13 2005-02-24 Kudos Pharmaceuticals Limited Aminopyrones and their use as atm inhibitors
CA2580229A1 (en) * 2004-09-20 2006-03-30 Kudos Pharmaceuticals Limited Dna-pk inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
BRPI0814294A2 (pt) 2007-07-19 2015-02-03 Metabolex Inc Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
CN107200749B (zh) 2013-03-12 2019-09-03 沃泰克斯药物股份有限公司 Dna-pk抑制剂
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
CN111053903A (zh) * 2019-12-26 2020-04-24 深圳市纳诺艾医疗科技有限公司 一种携带共振原子的核酸类似物的化合物的应用
US20240083917A1 (en) * 2021-01-05 2024-03-14 Shandong Xuanzhu Pharma Co., Ltd. Polycyclic Kinase Inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1994023714A1 (en) * 1993-04-09 1994-10-27 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JP4103968B2 (ja) * 1996-09-18 2008-06-18 株式会社半導体エネルギー研究所 絶縁ゲイト型半導体装置
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
WO2002000216A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
WO2005016919A1 (en) * 2003-08-13 2005-02-24 Kudos Pharmaceuticals Limited Aminopyrones and their use as atm inhibitors
CA2580229A1 (en) * 2004-09-20 2006-03-30 Kudos Pharmaceuticals Limited Dna-pk inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
JP5781720B2 (ja) * 2008-12-15 2015-09-24 ルネサスエレクトロニクス株式会社 半導体装置及び半導体装置の製造方法

Also Published As

Publication number Publication date
CN101754964A (zh) 2010-06-23
WO2009010761A1 (en) 2009-01-22
CA2693926A1 (en) 2009-01-22
CL2008002130A1 (es) 2009-01-02
RU2009149210A (ru) 2011-08-27
AU2008277418A1 (en) 2009-01-22
JP2010533694A (ja) 2010-10-28
US20090042865A1 (en) 2009-02-12
UY31232A1 (es) 2009-03-02
TW200918528A (en) 2009-05-01
EP2176254A1 (en) 2010-04-21
KR20100063701A (ko) 2010-06-11
AR067613A1 (es) 2009-10-14

Similar Documents

Publication Publication Date Title
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
CY2017016I1 (el) Αναστολεις πρωτεασωματος
CY2019009I2 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0814797A2 (pt) Inibidores dna-pk
SMT201600081B (it) Inibitore di bromodominio di benzodiazepina
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0910668A2 (pt) inibidores de proteína quinases
ATE522535T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0806898A2 (pt) Inibidores de mek
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
BRPI0918564A2 (pt) inibidores
BRPI0919818A2 (pt) inibidores de seprase seletivos
BRPI0922880A2 (pt) compostos inibidores de quinase
DK2066662T3 (da) Serinhydrolaseinhibitorer
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase
DK2240506T3 (da) IAP inhibitorer
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]